Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pilot study of IC43 immunogenicity and safety in mechanically ventilated ICU patients
2008-005037-30Phase 2Completed
- Sponsor
- Intercell AG
- Start
- Sep 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IC43 in Pseudomonal infection (3 arms), sponsored by Intercell AG. Primary endpoint: Primary immunogenicity at day 14. Started Sep 2008; status: completed.
02
Drugs
IC43
03
Conditions
Pseudomonal infection
Beyond the preview
Go deeper on 2008-005037-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005037-30.